TORONTO, June 15, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) (“Field Trip”), a leader in the development and delivery of psychedelic therapies, today announced that it has completed initial drug metabolism and pharmacokinetic (“DMPK”) studies for FT-104, its novel psychedelic compound in development. In-vitro preclinical studies confirmed that metabolism of…

Source

Previous articlePT248 – Pierre Bouchard – Somatic Therapy, Trauma, and the Nervous System
Next articlePharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression